Company intelligence / Profile preview

Acurable

London, England, United Kingdom

Ownership: Private
Development stage: Commercial

Overview

Acurable’s AcuPebble SA100 has received both CE mark in Europe and FDA clearance in the US for automated home diagnosis of obstructive sleep apnea. Clinical studies have shown over 90% accuracy compared to gold-standard polysomnography and at-home multi-channel polygraphy. The company is expanding its pipeline to address additional respiratory and cardiovascular conditions using the same platform.

Therapeutic areas: PulmonologyNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Acurable.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acurable.

Explore the full profile